26 results about "Amikacin" patented technology

A method for treating a flavivirus infection includes administering to a subject in need thereof a composition which includes at least one of gentamicin sulfate, netilmicin, tobramycin, paromomycin, amikacin, capreomycin, trifluoperazine, dihydrostreptomycin, hydroxychloroquine, thioridazine HCl, efavirenz, miltefosine, nystatin, micafungin, bleomycin, resminostat, montelukast, norfloxacin, nedaplatin and cephalothin, which can exhibit excellent growth inhibition or killing effects of various species of flavivirus genus.

The invention discloses a bacteriostatic composition which comprises a synergist and a bacteriostatic agent, the synergist is ethyl phenylacetate or a derivative thereof, and the bacteriostatic agent is selected from hydrogen peroxide, beta-lactam antibiotics, macrolide antibiotics and aminoglycoside antibiotics. The synergist disclosed by the invention is wide in synergistic effect spectrum range, and has a remarkable synergistic bacteriostatic effect when being combined with hydrogen peroxide, amoxicillin, ampicillin, benzylpenicillin potassium, erythromycin, azithromycin and amikacin; the antibacterial effect is weak when the compound is independently used, but the virulence of staphylococcus aureus can be remarkably reduced, the formation of hemolysin, staphylococcus flavin, enterotoxin and a biofilm can be inhibited, and meanwhile, the selective pressure on bacteria is favorably reduced due to the relatively low antibacterial activity, so that the occurrence of drug resistance is delayed; the method is suitable for various application scenes such as food processing industry.

The invention relates to the technical field of traditional Chinese medicine preparations, in particular to a traditional Chinese medicine spray for treating rhinitis and a preparation method thereof.The traditional Chinese medicine spray is prepared from flos magnoliae liliflorae, fructus xanthii, herba ephedrae, fructus forsythiae, flos lonicerae, radix angelicae, herba asari, menthol, herba centipedae and herba menthae. Refining to obtain a fluid extract; and mixing the fluid extract with a penetration enhancer consisting of aminoketone and menthol, a sodium hyaluronate mucous membrane repairing agent, a pH regulator, an isoosmotic adjusting agent and a preservative to prepare spray liquid medicine, and finally performing sterile filtration and filling. Through efficient extraction and synergism of composite auxiliary materials, the permeability and bioavailability of the medicine are remarkably improved, and the symptoms such as nasal obstruction and running nose can be quickly relieved; meanwhile, the anti-inflammatory function and the function of actively repairing the damaged nasal mucosa are achieved, and the recurrence rate is reduced from the source; the pH and osmotic pressure of the preparation are precisely adjusted, the use is comfortable, and the quality is stable and controllable.

The invention provides a method for simultaneously determining eight aminoglycoside antibiotics in cosmetics, and belongs to the technical field of medicines. By optimizing an HPLC-MS / MS (High Performance Liquid Chromatography-Mass Spectrometry / Mass Spectrometry) method, a method capable of simultaneously determining spectinomycin, tobramycin, kanamycin B, kanamycin, hygromycin B, streptomycin, dihydrostreptomycin and amikacin in cosmetics is established. The method is good in specificity, the eight aminoglycoside antibiotics can be effectively separated, interference of solvents and matrixes in cosmetics is avoided, and the accuracy of a detection result is ensured; within the range of 5-500 ng.mL <-1 >, a good linear relation is achieved, and the content of antibiotics in cosmetics can be accurately reflected; target antibiotics can still be reliably detected and quantified at low concentration; the method is good in precision and high in recovery rate and repeatability. The method provides reliable technical support for cosmetic risk monitoring, and provides scientific basis for perfecting related detection standards and supervision policies.

The application discloses an intelligent antibacterial hydrogel combined with a photosensitizer and an antibiotic as well as a preparation method and application thereof. The hydrogel takes oxidized dextran 40 as a hydrogel matrix, bonds 5-amino hexyl acetylpropionate into OAHAL through a Schiff base reaction, and is then crosslinked with amikacin to be prepared. The hydrogel has pH sensitivity, can effectively release drugs under an inflammatory slightly acidic environment, realizes on-demand release of the drugs, avoids overuse of the antibiotic, reduces toxic side effects, simultaneously loads two kinds of bactericidal drugs, 5-amino hexyl acetylpropionate and amikacin, and synergistically resists bacteria through two different mechanisms of photodynamic therapy and antibiotics, so that the antibacterial effect is significantly improved, and bacterial colonies caused by various types of wounds can be eliminated, and bacterial infection of a wound surface can be effectively prevented or treated.

The present application relates to the new use of Baotouweng decoction in the synergistic antibacterial effect of ceftriaxone, tetracycline and amikacin antibiotics. In the preparation of the composition or compound preparation, the dosage ratio of Baotouweng decoction and ceftriaxone, tetracycline and amikacin is between 6400:1-12800:1. The FIC index of Baotouweng decoction combined with ceftriaxone, amikacin or tetracycline is 0.1875-0.375, which is less than 0.5, that is, Baotouweng decoction combined with ceftriaxone, amikacin or tetracycline has synergistic antibacterial effect. The present application can effectively reduce the dosage of ceftriaxone, amikacin or tetracycline, and the MIC value of Baotouweng decoction combined with ceftriaxone, amikacin or tetracycline is reduced by 2-16 times compared with that of single use. Baotouweng decoction can be used as an antibacterial drug resistance reversal agent to improve the antibacterial therapeutic effect under the condition of reducing the dosage of antibacterial drugs.

The application discloses an N-(3-cyclobutyrolactone)-4-nitrophenyl butyryl amide and amikacin composition and application of the composition in treating chronic infection of drug-resistant bacteria. After the N-(3-cyclobutyrolactone)-4-nitrophenyl butyryl amide and the amikacin are combined, not only the sensitivity of pseudomonas aeruginosa to the amikacin can be obviously increased, but also the formation amount of the pseudomonas aeruginosa biofilm can be greatly reduced, so that the composition can be applied to preventing and treating chronic infection of drug-resistant pseudomonas aeruginosa.

The invention discloses application of amikacin in preparation of a medicine for treating melanoma, and relates to the technical field of biological medicine. The invention provides application of at least one of amikacin, pharmaceutically acceptable salts of amikacin, stereoisomers of amikacin, solvates of amikacin and polymorphic substances of amikacin in preparation of drugs for treating melanoma. In the invention, amikacin can inhibit proliferation, migration and invasion of melanoma cells; in a mouse transplantation tumor model, amikacin can also obviously delay tumor progression, and meanwhile obvious toxic reaction does not occur. Therefore, amikacin has the potential of serving as a new candidate drug for treating melanoma, can be used for treating melanoma, and provides a new research direction for reutilization of antibiotic drugs and treatment of melanoma.

Provided is a method for treating a newly diagnosed and untreated MAC lung infection comprising administering to the lungs of a patient for an administration period of at least about 6 months, a pharmaceutical composition comprising amikacin, or a pharmaceutically acceptable salt thereof, The pharmaceutical composition is aerosolized via a nebulizer to provide an aerosolized pharmaceutical composition comprising a mixture of free amikacin, or a pharmaceutically acceptable salt thereof, and liposomal complexed amikacin, or a pharmaceutically acceptable salt thereof, and the aerosolized pharmaceutical composition is administered via the nebulizer to the lungs of the patient once daily in a single dosing session. The treating comprises improving a respiratory symptom score as defined by one or more patient reported outcomes, during or subsequent to the administration period.

The application relates to the technical field of livestock reproduction, and particularly discloses a sperm microcapsule preparation and a preparation method; the sperm microcapsule preparation comprises a base liquid, carboxylated fullerene and sodium alginate; the base liquid comprises a sperm diluent, an amikacin mixed solution and egg yolk; the concentration of the carboxylated fullerene is 0-18 mu g / mL; and the concentration of the sodium alginate is 1%-2%. The application can reduce the damage of the microencapsulation process to sperm and improve the sperm quality in the sperm incubation process.

The invention relates to application of isochlorogenic acid C in preparation of a medicine for treating diseases related to drug-resistant escherichia coli, and belongs to the technical field of medicines. The invention provides an application of isochlorogenic acid C and / or an antibiotic in preparation of a medicine for treating diseases related to drug-resistant escherichia coli. The antibiotic is one of doxycycline, tetracycline, ciprofloxacin and amikacin. In-vivo and in-vitro experiments prove that chlorogenic acid C can enable drug-resistant escherichia coli to be re-sensitive to various antibiotics and has a synergistic effect with the antibiotics, the antibacterial effect of conventional antibiotics is improved, and a mouse abdominal cavity infection model further proves that ICAC combined with the antibiotics can relieve in-vivo escherichia coli infection, so that the antibacterial effect of the antibiotics is improved. A new strategy is provided for treating drug-resistant escherichia coli diseases.

The application discloses a combined drug sensitivity test method for rapidly detecting the synergistic effect of amikacin and ceftazidime-avibactam, and the method comprises the following steps: uniformly coating a to-be-detected bacterial suspension on an MH agar plate, firstly pasting two ATM paper sheets and two CZA paper sheets respectively, and ensuring that the four paper sheets are uniformly distributed on the plate; secondly, pasting a to-be-detected ATM drug sensitivity paper sheet on a to-be-detected CZA paper sheet, and indicating the CZA ATM ; thirdly, pasting a to-be-detected CZA drug sensitivity paper sheet on a to-be-detected ATM paper sheet, and indicating the ATM CZA ; fourthly, respectively dropping 20 μL of sterile normal saline on the CZA ATM and ATM CZA ; and finally, placing the plate in a 35℃ incubator for 8 hours, measuring the diameters of the bacteriostatic rings of ATM, CZA, ATM CZA and CZA ATM , and determining the synergistic effect according to the diameters of the bacteriostatic rings and the drug sensitivity breakpoint standard. The application has the advantages of simple operation, rapidness, accuracy, low cost and the like.

The application provides a method for preparing a beta crystal form of amikacin, comprising the following steps: (1) dissolving an alpha crystal form of amikacin in anhydrous ethanol or a mixed solution of anhydrous ethanol and acetone, and obtaining a beta crystal form of amikacin wet product through recrystallization; and (2) drying the beta crystal form of amikacin wet product in a drying device with a relative humidity of 70% to 100% at 40 to 70 DEG C under normal pressure for 2 to 10 hours or under vacuum for 2 to 18 hours, so as to obtain a beta crystal form of amikacin with an ethanol content of less than 0.5% by weight. In the application, by controlling the humidity of the drying environment when the product is dried, the ethanol can be effectively removed while the moisture content of the amikacin wet product is maintained, so as to reduce the ethanol content of the amikacin product, meet the requirement of the ICH guideline Q3C that the ethanol content is not more than 0.5% by weight, and greatly improve the safety of amikacin clinical medication.

The invention provides a salmonella typhimurium ArcB gene deleted strain as well as a construction method and application thereof, and belongs to the technical field of gene engineering. The construction method comprises the following steps: amplifying target DNA (deoxyribonucleic acid); the pKD46 plasmid is electrically transformed into an SL1344 competent cell, and then the targeting DNA is electrically transformed into the SL1344 containing the pKD46 plasmid, so that a deleted strain containing the Kan resistance gene is obtained; after the pCP20 plasmid is electrically transferred into the deleted strain containing the kan resistance gene, the pCP20 plasmid is eliminated; and after the sequencing is correct, obtaining the ArcB gene deleted strain SL1344 [delta] ArcB. The acid resistance and hypertonic resistance of the SL1344deltaArcB provided by the invention are remarkably weakened compared with those of WT, the sensitivity to penicillin, imipenem, kanamycin and amikacin is remarkably improved, the sensitivity to gentamicin is remarkably reduced, and the SL1344deltaArcB has important significance in research on the aspects of drug resistance, toxicity, vaccines and the like of salmonella typhimurium.

The application discloses a beta-lactamase and a gene for coding the beta-lactamase, and further discloses an expression cassette, a recombinant carrier, a recombinant cell or a recombinant bacteria, and a construction method of the recombinant bacteria, and further discloses the application of the beta-lactamase, the gene for coding the beta-lactamase, the expression cassette, the recombinant carrier, the recombinant cell or the recombinant bacteria, and the construction method of the recombinant bacteria in removing beta-lactam antibiotic pollution in the environment. The beta-lactamase gene is transformed into escherichia coli, so that the escherichia coli can hydrolyze beta-lactam antibiotics in the environment, including ampicillin, cefazolin, cefotaxime, imipenem and amikacin, and has great application value in eliminating beta-lactam antibiotic pollution in the environment.

The invention discloses a marine fungus Trichoderma, a quorum sensing inhibitor alpha, beta-unsaturated cyclopentanone compound as well as a preparation method and application of the quorum sensing inhibitor alpha, beta-unsaturated cyclopentanone compound. The alpha, beta-unsaturated cyclopentanone compound is separated from a fermentation culture of a marine fungus Trichoderma sp.6791, and has bacterial biofilm formation inhibition and quorum sensing system related virulence factors, and tests prove that the alpha, beta-unsaturated cyclopentanone Hypocreone C can inhibit the formation of a bacterial biofilm and quorum sensing system related virulence factors under the condition of not inhibiting the growth of pseudomonas aeruginosa, and can inhibit the formation of the quorum sensing system related virulence factors under the condition of not inhibiting the growth of pseudomonas aeruginosa. The pseudomonas aeruginosa can effectively inhibit the formation of a pseudomonas aeruginosa biofilm and obviously inhibit the secretion of pyocyanine and rhamnolipid virulence factors in a quorum sensing system, so that the pathogenicity and virulence of bacteria are reduced, and the generation of multiple drug resistance of the bacteria is slowed down. When the compound Hypocrenone C provided by the invention is combined with antibiotic drugs such as amikacin, the inhibition effect of amikacin on pseudomonas aeruginosa can be remarkably enhanced; the cyclopentanone compound provided by the invention provides a lead compound for developing novel quorum sensing inhibitors and antibacterial drugs, and has potential application as antibacterial drugs.

The invention relates to the field of nucleic acid detection, and provides a primer group for detecting a mycobacterium tuberculosis complex group and drug resistance thereof and application of the primer group. According to the method for detecting the drug resistance of the mycobacterium tuberculosis complex as well as kanamycin, amikacin, capreomycin, fluoroquinolones (ofloxacin, levofloxacin and moxifloxacin) and linezolid, provided by the invention, specific detection on the mutation sites and specific sequences can be realized; the method has the advantages of high accuracy, high sensitivity, good repeatability, low cost, short detection period, visual result, no need of signal intervention and the like. The method is more in line with the gene mutation characteristics of the mycobacterium tuberculosis drug-resistant strain, overcomes the defect that the number of SNP sites detected at a time in the prior art is small, has the advantages of being high in accuracy and sensitivity, good in repeatability, low in cost and short in detection period, and has a very good application prospect.

The invention belongs to the technical field of membrane cleaning agents, and particularly relates to a membrane cleaning agent for removing microbial pollution as well as a preparation method and application of the membrane cleaning agent. The membrane cleaning agent comprises the following components: a stripping agent, a non-oxidized bactericide, a biological enzyme, an enzyme stabilizer, a bactericidal synergist and water, the stripping agent is an epoxy alkyl compound; the enzyme stabilizer is glycerol and / or propylene glycol; the bactericidal synergist is trimethoprem and / or diamethoprem, and the bactericidal synergist is trimethoprem and / or diamethoprem. The cleaning agent is characterized in that the stripping agent, the non-oxidation type bactericide, the biological enzyme, the enzyme stabilizer and the sterilization synergist are used as main components, the cleaning effect is synergistically improved from the two aspects of enhancing the stripping and elution effect and the sterilization effect of the cleaning agent, and microbial contamination on a membrane is efficiently removed; the membrane flux is greatly improved compared with that before cleaning, and the desalting performance is basically the same as that before cleaning.

The invention provides nitrate reducing bacteria C381 as well as a method and application thereof. The nitrate reducing bacteria C381 is preserved in China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCC No.36842; the invention provides a novel oral cavity probiotic nitrate reducing bacteria C381, the nitrate reducing bacteria C381 has an inhibition effect on periodontal disease bacteria, and the nitrate reducing bacteria C381 is sensitive to antibiotics such as erythromycin, piperacillin, minocycline, doxycycline, cefazolin, tetracycline, amikacin, gentamicin, vancomycin and cefoperazone, and can be used for preparing oral cavity probiotics for treating periodontal disease bacteria. And the product has good survival ability in the oral cavity.

The present invention belongs to the field of pharmaceutical technology and specifically relates to the use of myrtle ketone derivatives in the preparation of antibacterial drugs and the antibacterial drugs themselves. A novel class of myrtle ketone derivatives synthesized in the present invention exhibits inhibitory activity against Gram-positive bacteria, among which compound 27 is the most potent DNA gyrase and Topo IV inhibitor. Biological activity assays demonstrate that compound 27 not only exhibits rapid bactericidal activity against methicillin-resistant Staphylococcus aureus, but also exhibits low toxicity, is less likely to induce bacterial resistance, and exhibits synergistic effects with first-line antibacterial drugs such as ofloxacin, amikacin, cefpiramide, and ceftazidime, making it a potential candidate for a new antibacterial drug.

The invention provides bacillus C367 as well as a method and application thereof. The bacillus C367 is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCC No.36841; the bacillus C367 is separated from the Inner Mongolia cheese; the bacillus C367 can be used for preparing medicines for treating or preventing periodontal diseases; the invention provides a novel oral cavity probiotic bacillus C367, the bacillus C367 has an inhibition effect on periodontal disease bacteria, and the bacillus C367 is sensitive to antibiotics such as minocycline, amikacin, tetracycline, erythromycin, cefoperazone, streptomycin, kanamycin, gentamicin, vancomycin and ceftriaxone, and has good survival ability in an oral cavity.

The invention belongs to the technical field of medicines, and particularly relates to application of a myrtle ketone derivative in preparation of an antibacterial drug and the antibacterial drug. A novel myrtle ketone derivative is synthesized, the myrtle ketone derivative has inhibitory activity on gram-positive bacteria, and a compound 27 is the most effective DNA (deoxyribonucleic acid) gyrase and Topo IV inhibitor. Biological activity determination shows that the compound 27 not only has the advantage of rapid sterilization on methicillin-resistant staphylococcus aureus, but also has low toxicity, is not easy to induce bacterial drug resistance, and shows a synergistic effect with first-line antibacterial drugs such as ofloxacin, amikacin, cefpiramide and ceftazidime; this makes it a potential candidate for novel antibacterial agents.

The invention belongs to the technical field of animal medicine, and particularly relates to a tortoise respiratory tract infection non-irritant nebulization treatment medicine and a using method thereof.The medicine comprises a first round of nebulization medicine and a second round of nebulization medicine, and the first round of nebulization medicine comprises 10 ml of normal saline and 0.2 ml of aminophylline; and the second-round atomized medicine comprises 10ml of normal saline, 50mg of amikacin, 1mg of dexamethasone and 10mg of ribavirin, and is formed by mixing the normal saline, the amikacin, the dexamethasone and the ribavirin. The using method comprises the steps of early-stage preparation, medicine preparation and atomization operation. According to the tortoise respiratory tract infection non-irritant atomization treatment medicine and the using method thereof, staged synergistic treatment is achieved, and the progressive administration logic of spasmolysis and infection resistance is initiated for the first time; a non-irritant formula is adopted, and zero-damage treatment of the respiratory tracts of turtles is achieved for the first time; the atomization box is used for simulating the original environment of the Dabie mountain, the vicious circle of'stress-food refusal-immunity decline 'of the existing turtles is solved, the integration of'treatment and maintenance' is realized through environment simulation and time control, and the healing effect is improved.

The present application belongs to the field of chemistry, and particularly relates to a three-dimensional gallium metal organic framework with fluorescence detection function and a synthesis and application method. A gallium metal organic framework compound with fluorescence recognition function has a chemical formula of {[(CH3)2(NH2)Ga(PPTA)]·0.5DMF} n . A preparation method of the gallium metal organic framework chemical substance is as follows: gallium nitrate, 4,4',4'',4'''-(4,4'-(1,4-phenylene)bis(pyridine-6,4,2-triyl))tetraanisic acid (PPTA) and oleic acid are added into a mixed solution of ethanol and N,N-dimethylformamide (DMF), stirred uniformly, and heated at constant temperature to obtain red block crystals, which are the gallium metal organic framework compound with fluorescence recognition function. The gallium metal organic framework compound is applied to detect aminoglycoside antibiotic amikacin. The fluorescence property is derived from ligand luminescence. The gallium metal organic framework material constructed shows different fluorescence properties from the ligand, can have specific fluorescence recognition function for amikacin, and has high sensitivity, anti-interference and recyclability.

The invention discloses an aztreonam and avibactam sodium freeze-dried preparation for injection and a preparation method thereof, and belongs to the technical field of pharmaceutical preparations. Comprising the following steps: pre-cooling a freeze dryer plate layer to 5 DEG C; the method comprises the following steps: filling a freeze-drying solution containing aztreonam and avibactam sodium into a penicillin bottle, and putting the penicillin bottle filled with the freeze-drying solution into a box; the temperature is reduced to-35 DEG C to-50 DEG C within 2-6 hours, and the temperature is kept for 2-6 hours for freezing; the vacuum degree is reduced to 0.0-0.5 mbar, the temperature is increased to-25 DEG C to-5 DEG C within 2-8 hours, and heat preservation is conducted for 50-80 hours; raising the temperature to 20-30 DEG C in 2-8 hours, vacuumizing for 0.0-0.4 mbar, and keeping for 2-6 hours, raising the temperature to 40-50 DEG C in 0.5-2 hours, vacuumizing for 0.0-0.4 mbar, and keeping for 4-8 hours, and raising the temperature to 40-50 DEG C in 0.5-2 hours, vacuumizing for 0.0-0.4 mbar, and keeping for 4-8 hours; the concentration of aztreonam in the freeze-drying solution is 1.5 g / mL, the concentration of avibactam sodium is 0.5 g / mL, and the concentration of L-arginine in the solution is 0.09-0.135 g / mL. Through a conventional freeze-drying process, the prepared freeze-dried product has few appearance defects, the water content is lower than 1%, and the freeze-dried product has good re-dissolvability, does not have dendritic crystals during re-dissolution and has good stability and safety.

The invention relates to the technical field of biomedicine, and provides application of combination of bacteriophage and antibiotic in preparation of a drug-resistant bacterial infection drug, the bacteriophage is acinetobacter baumannii or mycobacterium tuberculosis bacteriophage, and the antibiotic comprises one or more of amikacin, fosfomycin and polymyxin B. The invention provides the application of the combination of the bacteriophage and the antibiotic in the aspect of preparing the drug-resistant bacterial infection drug, the synergistic interaction can be realized, the drug resistance is reduced, the bacteriocidal spectrum is expanded, and the support is provided for the early intervention, accurate effect generation and prognosis improvement of the drug-resistant bacterial infection.